Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 2/20 | 0.58 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl N-Methylcarbamate SCHEMBL6510776 | 0.98 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL6461910 | 0.96 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL6444513 | 0.94 | ALDH1A1 (0.61) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL5156651 | 0.93 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL5586442 | 0.93 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL11110653 | 0.91 | CTSS (0.53) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL28652926 | 0.90 | MEN1 (0.56) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL4127079 | 0.88 | EPHX1 (0.51) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| Benzyl N-Methylcarbamate SCHEMBL4139606 | 0.87 | EPHX1 (0.50) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL21597890 | 0.87 | LMNA (0.72) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | claimed |
| CN-112852509-A | Gasoline additive, composition thereof and gasoline composition | 广东月福汽车用品有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | claimed |
| US-20190185476-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | claimed |
| EP-3458455-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-03-27 | — | — | EP | claimed |
| WO-2017198744-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-23 | — | — | WO | claimed |
| CN-106829451-A | A kind of rotary sample introduction mobile device of carbon tetrachloride monitor straight line and its method of work | 徐州工程学院 | 2017-06-13 | — | — | CN | claimed |
| US-20080312310-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2008-12-18 | — | — | US | claimed |
| EP-1554265-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1008590-B1 | Process for preparing optically active oxazolidinone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2006-10-11 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| EP-1008590-A1 | Process for preparing optically active oxazolidinone derivative | Takasago International Corporation (JP) | 2000-06-14 | — | — | EP | claimed |
| EP-0973768-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | claimed |
| WO-1998043970-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-08 | — | — | WO | claimed |
| US-RE35886-E | ENDOTHELIN-CONVERTING ENZYME INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-01 | — | — | US | claimed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0518299-A2 | Phosphonic acid derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-16 | — | — | EP | claimed |
| EP-0308885-A1 | Derivatives of d-glutamic acid and d-aspartic acid | ABBOTT LABORATORIES (US) | 1989-03-29 | — | — | EP | claimed |
| WO-1989002431-A1 | DERIVATIVES OF D-GLUTAMIC ACID AND D-ASPARTIC ACID | ABBOTT LABORATORIES (US) | 1989-03-23 | — | — | WO | claimed |
| US-4610983-A | N-acyl acidic amino acid diamide derivative, a salt thereof, and an anti-ulcer agent containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312310-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | ALDH1A1 2631/4885NPC1 170/4885RAB9A 2909/4885 |
| US-20190185476-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | SQOR, HCCS, CBR1 | ALDH1A1 809/4885NPC1 1797/4885RAB9A 2851/4885 |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HAVCR2, CYP3A43, CYP3A5 | ALDH1A1 262/4885NPC1 305/4885RAB9A 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.